GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of API source: the version I wish someone had shown me in week 1 — 44 comments in the full submission. View in context.
3.6k
c/compounding·submitted 1 year ago by u/hugo_bergstrom

API source: the version I wish someone had shown me in week 1

Discussionbranch of 11 comments

Confession thread, sort of. I went from 0.5mg to 12.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 18 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have…

Read the full submission and all 44 comments →

This branch

11 comments, started 1 year ago
u/escrow_evangelist103 points·1 year ago

Which state? Rules vary.

replysharereportpermalink
u/rekha_mwangi84 points·1 year ago

Yeah, 503A and 503B are different regulatory animals.

replysharereportpermalink
[removed]73 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/sofia_danquah24 points·1 year ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/pavel_kravchenko44 points·1 year ago

the 503A/503B distinction is load-bearing, do not blur it

replysharereportpermalink
u/teodor_duarte29 points·1 year ago·edited

the 503A/503B distinction is load-bearing, do not blur it

Adding to this: API source is doing more work than the comment implies.

replysharereportpermalink
u/hugo_bergstromOP13 points·1 year ago

the shortage list is temporary, it ends and compounding becomes illegal again

replysharereportpermalink
u/hugo_bergstromOP66 points·1 year ago·edited

Moved states and the compounding landscape changed completely. Different rules, different pharmacies, different costs.

replysharereportpermalink
u/niels_roos42 points·1 year ago

API transparency is the question that separates good compounders from sketchy ones

replysharereportpermalink
u/rina_sobczak9 points·1 year ago

Are we talking 503A or 503B?

replysharereportpermalink
u/step_count_stan18 points·1 year ago

Did they tell you their API source or dodge the question?

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.